• White, Cameron
• Lee, Bruce
• Martinez, Marie F.
• Huang, Susan
• Singh, Raveena D.
• Wasserman, Michael R.
• Scannell, Sheryl A.
• Weatherwax, Colleen
• Gussin, Gabrielle
• Bartsch, Sarah M.
• Leff, Bruce

Abstract

<jats:title>Abstract</jats:title><jats:sec id="S0899823X24000096_as1"><jats:title>Objective:</jats:title><jats:p>Nursing home residents may be particularly vulnerable to coronavirus disease 2019 (COVID-19). Therefore, a question is when and how often nursing homes should test staff for COVID-19 and how this may change as severe acute respiratory coronavirus virus 2 (SARS-CoV-2) evolves.</jats:p></jats:sec><jats:sec id="S0899823X24000096_as2"><jats:title>Design:</jats:title><jats:p>We developed an agent-based model representing a typical nursing home, COVID-19 spread, and its health and economic outcomes to determine the clinical and economic value of various screening and isolation strategies and how it may change under various circumstances.</jats:p></jats:sec><jats:sec id="S0899823X24000096_as3"><jats:title>Results:</jats:title><jats:p>Under winter 2023–2024 SARS-CoV-2 omicron variant conditions, symptom-based antigen testing averted 4.5 COVID-19 cases compared to no testing, saving $191 in direct medical costs. Testing implementation costs far outweighed these savings, resulting in net costs of $990 from the Centers for Medicare &amp; Medicaid Services perspective, $1,545 from the third-party payer perspective, and $57,155 from the societal perspective. Testing did not return sufficient positive health effects to make it cost-effective [$50,000 per quality-adjusted life-year (QALY) threshold], but it exceeded this threshold in ≥59% of simulation trials. Testing remained cost-ineffective when routinely testing staff and varying face mask compliance, vaccine efficacy, and booster coverage. However, all antigen testing strategies became cost-effective (≤$31,906 per QALY) or cost saving (saving ≤$18,372) when the severe outcome risk was ≥3 times higher than that of current omicron variants.</jats:p></jats:sec><jats:sec id="S0899823X24000096_as4"><jats:title>Conclusions:</jats:title><jats:p>SARS-CoV-2 testing costs outweighed benefits under winter 2023–2024 conditions; however, testing became cost-effective with increasingly severe clinical outcomes. Cost-effectiveness can change as the epidemic evolves because it depends on clinical severity and other intervention use. Thus, nursing home administrators and policy makers should monitor and evaluate viral virulence and other interventions over time.</jats:p></jats:sec>

Topics

• impedance spectroscopy
• simulation
• size-exclusion chromatography